Low-cost HPV testing and the prevalence of cervical infection in asymptomatic populations in Guatemala
Hong Lou,
Eduardo Gharzouzi,
Sarita Polo Guerra,
Joël Fokom Domgue,
Julie Sawitzke,
Guillermo Villagran,
Lisa Garland,
Joseph F. Boland,
Sarah Wagner,
Héctor Rosas,
Jami Troxler,
Heidi McMillen,
Bailey Kessing,
Enrique Alvirez,
Miriam Castillo,
Hesler Morales,
Victor Argueta,
Andert Rosingh,
Femke J. H. B. van Aerde-van Nunen,
Griselda Lopez,
Herbert M. Pinedo,
Mark Schiffman,
Michael Dean,
Roberto Orozco
Affiliations
Hong Lou
Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, Leidos Biomedical Research, Inc., National Laboratory for Cancer Research
Eduardo Gharzouzi
Instituto de Cancerologia
Sarita Polo Guerra
Instituto de Cancerologia
Joël Fokom Domgue
Cancer Genetics Branch
Julie Sawitzke
Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, Leidos Biomedical Research, Inc., National Laboratory for Cancer Research
Guillermo Villagran
Instituto de Cancerologia
Lisa Garland
Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, Leidos Biomedical Research, Inc., National Laboratory for Cancer Research
Joseph F. Boland
Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, Leidos Biomedical Research, Inc., National Laboratory for Cancer Research
Sarah Wagner
Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, Leidos Biomedical Research, Inc., National Laboratory for Cancer Research
Héctor Rosas
Department of Gynecology and Obstetrics, Hospital General San Juan de Dios
Jami Troxler
Cancer Research Technology Program, Leidos Biomedical Research, Inc., National Cancer Institute
Heidi McMillen
Cancer Research Technology Program, Leidos Biomedical Research, Inc., National Cancer Institute
Bailey Kessing
Cancer Research Technology Program, Leidos Biomedical Research, Inc., National Cancer Institute
Enrique Alvirez
Hospital Central Universitario “Dr. Antonio M Pineda”
Miriam Castillo
Instituto de Cancerologia
Hesler Morales
Instituto de Cancerologia
Victor Argueta
Department of Pathology, Hospital General San Juan de Dios
Andert Rosingh
Medical Laboratory Services
Femke J. H. B. van Aerde-van Nunen
Medical Laboratory Services
Griselda Lopez
Department of Pathology, Hospital General San Juan de Dios
Herbert M. Pinedo
Fundashon Prevenshon
Mark Schiffman
Cancer Genetics Branch
Michael Dean
Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute
Roberto Orozco
Department of Pathology, Hospital General San Juan de Dios
Abstract Background A low cost and accurate method for detecting high-risk (HR) human papillomavirus (HPV) is important to permit HPV testing for cervical cancer prevention. We used a commercially available HPV method (H13, Hybribio) which was documented to function accurately in a reduced volume of cervical specimen to determine the most prevalent HPV types and the distribution of HPV infections in over 1795 cancer-free women in Guatemala undergoing primary screening for cervical cancer by cytology. Methods HR-HPV detection was attempted in cervical samples from 1795 cancer-free women receiving Pap smears using the Hybribio™ real-time PCR assay of 13 HR types. The test includes a globin gene internal control. HPV positive samples were sequenced to determine viral type. Age-specific prevalence of HPV was also assessed in the study population. Results A total of 13% (226/1717) of women tested HPV+, with 78 samples (4.3%) failing to amplify the internal control. The highest prevalence was found in younger women (< 30 years, 22%) and older ones (≥60 years, 15%). The six most common HR-HPV types among the 148 HPV+ typed were HPV16 (22%), HPV18 (11%), HPV39 (11%), HPV58 (10%), HPV52 (8%), and HPV45 (8%). Conclusions In this sample of cancer free women in Guatemala, HPV16 was the most prevalent HR type in Guatemala and the age-specific prevalence curve peaked in younger ages. Women in the 30-59-year age groups had a prevalence of HR-HPV of 8%, however, larger studies to better describe the epidemiology of HPV in Guatemala are needed.